Stuart M. Sprague

Stuart M. Sprague

Nephrology | Transplant Surgery

1000 Central St.
Suite 800
Evanston, IL 60201

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 86 publications

Correction to: Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study.

Correction to: Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study.

Journal: Kidney360

Published: April 17, 2026

Sustained improvement in renal function with palopegteriparatide in adults with chronic hypoparathyroidism: 2-year results from the phase 3 PaTHway-trial.

Sustained improvement in renal function with palopegteriparatide in adults with chronic hypoparathyroidism: 2-year results from the phase 3 PaTHway-trial.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Published: January 30, 2026

Managing Dysregulated Vitamin D Metabolism in CKD: Time to Update Conventional Wisdom?

Managing Dysregulated Vitamin D Metabolism in CKD: Time to Update Conventional Wisdom?

Journal: Kidney360

Published: August 26, 2025

A Pan-Inhibitor of Phosphate Transporters AP306 in Hemodialysis Patients.

A Pan-Inhibitor of Phosphate Transporters AP306 in Hemodialysis Patients.

Journal: Kidney international reports

Published: June 09, 2025

An update on investigation and management of renal bone disease.

An update on investigation and management of renal bone disease.

Journal: Current opinion in endocrinology, diabetes, and obesity

Published: March 28, 2025

Extended-Release Calcifediol Normalized 1,25-Dihydroxyvitamin D and Prevented Progression of Secondary Hyperparathyroidism in Hemodialysis Patients in a Pilot Randomized Clinical Trial.

Extended-Release Calcifediol Normalized 1,25-Dihydroxyvitamin D and Prevented Progression of Secondary Hyperparathyroidism in Hemodialysis Patients in a Pilot Randomized Clinical Trial.

Journal: American journal of nephrology

Published: March 20, 2025

Tight Phosphate Control in ESKD Patients Is Warranted: PRO.

Tight Phosphate Control in ESKD Patients Is Warranted: PRO.

Journal: Kidney360

Published: December 13, 2024

Adjunctive Active Vitamin D Decreases Kidney Function during Treatment of Secondary Hyperparathyroidism with Extended-Release Calcifediol in Non-Dialysis Chronic Kidney Disease in a Randomized Trial.

Adjunctive Active Vitamin D Decreases Kidney Function during Treatment of Secondary Hyperparathyroidism with Extended-Release Calcifediol in Non-Dialysis Chronic Kidney Disease in a Randomized Trial.

Journal: American journal of nephrology

Published: December 11, 2024

Sustained Reduction of Elevated Intact Parathyroid Hormone Concentrations with Extended-Release Calcifediol Slows Chronic Kidney Disease Progression in Secondary Hyperparathyroidism Patients.

Sustained Reduction of Elevated Intact Parathyroid Hormone Concentrations with Extended-Release Calcifediol Slows Chronic Kidney Disease Progression in Secondary Hyperparathyroidism Patients.

Journal: American journal of nephrology

Published: July 26, 2024

Effectiveness of tenapanor for treating hyperphosphatemia in patients receiving dialysis: a plain language summary of the OPTIMIZE study.

Effectiveness of tenapanor for treating hyperphosphatemia in patients receiving dialysis: a plain language summary of the OPTIMIZE study.

Journal: Current medical research and opinion

Published: July 23, 2024

Tenapanor: A Phosphate Absorption Inhibitor for the Management of Hyperphosphatemia in Patients With Kidney Failure.

Tenapanor: A Phosphate Absorption Inhibitor for the Management of Hyperphosphatemia in Patients With Kidney Failure.

Journal: Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation

Published: April 16, 2024

Incorporation of Calcimimetics into End-Stage Kidney Disease Bundle: Changes in Etelcalcetide Utilization and Parathyroid Hormone Control following End of Transitional Drug Add-On Payment Adjustment Designation.

Incorporation of Calcimimetics into End-Stage Kidney Disease Bundle: Changes in Etelcalcetide Utilization and Parathyroid Hormone Control following End of Transitional Drug Add-On Payment Adjustment Designation.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: March 20, 2024

Showing 1-12 of 86

Last Updated: 09/26/2026